5′-nitro-indirubinoxime induces G2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells

Cancer Letters

Volumn 274, Issue 1, 2009, Pages 72-77

  Kim, Soo A ^a   Kim, Si Wouk ^b   Chang, Sunghoe ^c   Yoon, Jung Hoon ^b   Ahn, Sang Gun ^b  

^a Dongguk University   (South Korea)

^b Chosun University   (South Korea)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

5 nitro indirubinoxime; Apoptosis; Cell cycle; Indirubin; PLK1

Indexed keywords

5' FLUORO INDIRUBINOXIME; 5' NITRO INDIRUBINOXIME; 5' TRIMETHYLACETAMINO INDIRUBINOXIME; ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; INDOLE DERIVATIVE; PROTEIN P16; PROTEIN P21; UNCLASSIFIED DRUG; 5' NITROINDIRUBINOXIME; 5'-NITROINDIRUBINOXIME; CASPASE; CCND1 PROTEIN, HUMAN; CCND2 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ONCOPROTEIN; OXIME; POLO LIKE KINASE 1; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOUTH CARCINOMA; PRIORITY JOURNAL; TUMOR GROWTH; WESTERN BLOTTING; CELL DIVISION; CELL STRAIN KB; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUTH TUMOR; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL CYCLE PROTEINS; CELL DIVISION; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; G1 PHASE; G2 PHASE; HUMANS; INDOLES; KB CELLS; MOUTH NEOPLASMS; OXIMES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING;

EID: 57749115903     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.08.033     Document Type: Article

References (29)

1. Hsu B. The use of herbs as anticancer agents. Am. J. Chin. Med. 8 (1980) 301-306
2. Zhang Z.N., Liu E.K., Zheng T.L., and Li D.G. Treatment of chronic myelocytic leukemia (CML) by traditional Chinese medicine and Western medicine alternately. J. Tradit. Chin. Med. 5 (1985) 246-248
3. Qin G.W., and Xu R.S. Recent advances on bioactive natural products from Chinese medicinal plants. Med. Res. Rev. 18 (1998) 375-382
4. Han J. Traditional Chinese medicine and the search for new antineoplastic drugs. J. Ethnopharmacol. 24 (1988) 1-17
5. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., Eisenbrand G., and Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J. Biol. Chem. 276 (2001) 251-260
6. Kunikata T., Tatefuji T., Aga H., Iwaki K., Ikeda M., and Kurimoto M. Indirubin inhibits inflammatory reactions in delayed-type hypersensitivity. Eur. J. Pharmacol. 410 (2000) 93-100
7. Ma M.Z., and Yao B.Y. Progress in indirubin treatment of chronic myelocytic leukemia. J. Tradit. Chin. Med. 3 (1983) 245-248
8. Xiao Z., Hao Y., Liu B., and Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma 43 (2002) 1763-1768
9. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E.M., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., and Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1 (1999) 60-67
10. Eisenbrand G., Hippe F., Jakobs S., and Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J. Cancer Res. Clin. Oncol. 130 (2004) 627-635
11. Merz K.H., Schwahn S., Hippe F., Muhlbeyer S., Jakobs S., and Eisenbrand G. Novel indirubin derivatives, promising anti-tumor agents inhibiting cyclin-dependent kinases. Int. J. Clin. Pharmacol. Ther. 42 (2004) 656-658
12. Marko D., Schatzle S., Friedel A., Genzlinger A., Zankl H., Meijer L., and Eisenbrand G. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer 84 (2001) 283-289
13. Nam S., Buettner R., Turkson J., Kim D., Cheng J.Q., Muehlbeyer S., Hippe F., Vatter S., Merz K.-H., Eisenbrand G., and Jove R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. USA 102 (2005) 5998-6003
14. Xie Y., Liu Y., Ma C., Yuan Z., Wang W., Zhu Z., Gao G., Liu X., Yuan H., Chen R., Huang S., Wang X., Zhu X., Wang X., Mao Z., and Li M. Indirubin-3′-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci. Lett. 367 (2004) 355-359
15. Damiens E., Baratte B., Marie D., Eisenbrand G., and Meijer L. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 20 (2001) 3786-3797
16. Duensing S., Duensing A., Lee D.C., Edwards K.M., Piboonniyom S.O., Manuel E., Skaltsounis L., Meijer L., and Munger K. Cyclin-dependent kinase inhibitor indirubin-3′-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 23 (2004) 8206-8215
17. Kim S.A., Kim Y.C., Kim S.W., Lee S.H., Min J.J., Ahn S.G., and Yoon J.H. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin. Cancer Res. 13 (2007) 253-259
18. Hansen M.B., Nielsen S.E., and Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119 (1989) 203-210
19. Glover D.M., Hagan I.M., and Tavares A.A. Polo-like kinases: a team that plays throughout mitosis. Genes Dev. 12 (1998) 3777-3787
20. Kotani S., Tugendreich S., Fujii M., Jorgensen P.M., Watanabe N., Hoog C., Hieter P., and Todokoro K. PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. Mol. Cell 1 (1998) 371-380
21. Yuan J., Eckerdt F., Bereiter-Hahn J., Kurunci-Csacsko E., Kaufmann M., and Strebhardt K. Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 21 (2002) 8282-8292
22. Toyoshima-Morimoto F., Taniguchi E., Shinya N., Iwamatsu A., and Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410 (2001) 215-220
23. Takahashi T., Sano B., Nagata T., Kato H., Sugiyama Y., Kunieda K., Kimura M., Okano Y., and Saji S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 94 (2003) 148-152
24. Simizu S., and Osada H. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat. Cell Biol. 2 (2000) 852-854
25. Liu X., and Erikson R.L. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc. Natl. Acad. Sci. USA 99 (2002) 8672-8676
26. Danial N.N., and Korsmeyer S.J. Cell death: critical control points. Cell 116 (2004) 205-219
27. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
28. Boatright K.M., and Salvesen G.S. Mechanisms of caspase activation. Curr. Opin. Cell Biol. 15 (2003) 725-731
29. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 326 (1997) 1-16